Clinical Trials · NCT00521781
Study of Abraxane Plus Hormonal Therapy as Initial Treatment of Unresectable or Metastatic Prostate Cancer
- Phase
- Phase 2
- Recruitment status
- Terminated
- Sponsor
- The Methodist Hospital Research Institute
- Enrollment
- 14
- Start date
- Aug 2007
- Locations
- 1 site, United States
- Primary endpoint
- Assess the clinical benefit as measured by time to tumor progression of Abraxane plus hormonal therapy when applied to previously untreated patients with unresectable or metastatic adenocarcinoma of the prostate.